Acute Liver Failure Market Size

Acute Liver Failure Market size is anticipated to reach USD 50 Billion by the end of 2036, growing at a CAGR of 6% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of acute liver failure was USD 24 Billion. There has been a surge in the number of people suffering from liver problems Because alcohol causes certain liver cells to die, a significant increase in alcohol use is one of the main causes of liver problems. As per a report, consuming alcohol results in death and disability at a relatively young age. Approximately 13.5% of all deaths in adults between the ages of 20 and 39 can be linked to alcohol use.

In addition, some treatment approaches, such as supportive medical care and medicines, aim to support liver function and regeneration, which may allow liver function to return to normal. Patients with acute liver failure can also have higher survival rates with prompt and adequate care, particularly if they receive liver transplantation or other sophisticated procedures.

Frequently Asked Questions (FAQ)

Growing prevalence of obesity, the increased geriatric population, and increased technological advancements in liver disease diagnosis are the major factors driving the growth of the acute liver failure market.

The market size of acute liver failure is anticipated to attain a CAGR of 6% over the forecast period, i.e., 2024 - 2036.

The major players in the market are Ipsen, Gilead Sciences, Inc., Pfizer Inc., Novartis AG, Bristol Myers Squibb, AbbVie Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Abbott Laboratories, Zydus Pharmaceuticals Inc. and others.

The liver transplant segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North America region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.

Acute Liver Failure Market Size